Lipid Nanoparticle Formulation for Localized mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA drug delivery systems, particularly lipid nanoparticles (LNPs), face challenges with off-target toxicity and systemic distribution, leading to reduced efficacy and increased side effects due to non-specific tissue targeting, especially after intramuscular or intratumoral injections.
Innovation Solution
A lipid-based topical injection formulation is developed, incorporating a Long-Acting SusTained delivering lipid and an ionizable lipid, which forms nanoparticles that electrostatically bind to mRNA, reducing off-target effects and enhancing peak concentration and bioavailability at the injection site, while prolonging the expression time of drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional lipid nanoparticles (LNPs) are used for mRNA delivery, then mRNA can be delivered to target tissues, but off-target toxicity occurs and systemic distribution increases, reducing therapeutic efficacy
Solution Approach 1:
The patent modifies the LNP formulation to achieve localized action at the injection site. By incorporating specific lipid components and optimizing particle characteristics, the mRNA delivery system concentrates its effect locally in the muscle tissue rather than distributing systemically, thereby improving therapeutic efficacy while reducing off-target toxicity.
Solution Approach 2:
The patent uses lipid nanoparticles as intermediaries to deliver mRNA to target tissues. By carefully designing the LNP composition and properties, the system acts as a controlled mediator that releases mRNA locally at the injection site, preventing premature systemic distribution and reducing off-target effects.
2Area of stationary object
If mRNA is delivered systemically, then broad tissue coverage is achieved, but off-target toxicity increases and therapeutic index decreases
Solution Approach 1:
The patent employs local quality by designing the LNP formulation to concentrate mRNA delivery at the injection site rather than distributing systemically. This localized delivery approach maintains high drug concentration where needed while minimizing exposure and toxicity in other tissues.
Solution Approach 2:
The patent segments the delivery process by using intramuscular injection to confine the LNP-mRNA complex to a specific anatomical location. This spatial segmentation prevents systemic distribution and reduces off-target toxicity while maintaining effective local tissue coverage.
3Duration of action of moving object
If mRNA half-life is extended through LNP optimization, then patient compliance improves, but formulation complexity increases
Solution Approach 1:
The patent extends mRNA action time by optimizing formulation parameters such as lipid composition, particle size, and charge characteristics. By carefully adjusting these parameters, the system achieves prolonged local retention and sustained mRNA release without requiring overly complex formulation designs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly reduces off-target effects, increases drug expression at the injection site, and prolongs the therapeutic effect, potentially improving the clinical outcomes of mRNA-based therapies by targeted delivery and reduced systemic toxicity.
Implementation Method 1
a lipid nanoparticle formed by combining a Long-Acting SusTained delivering lipid such as a cationic lipid with a permanently positive form (DOTAP, EPC, etc.) and an ionizable lipid and then binding the two to mRNA sequence through electrostatic interaction
Data Source
AI summary
This disclosure relates to a lipid-based topical injection formulation containing a Long-Acting SusTained delivering lipid, a structured lipid, a polymer-conjugated lipid and an ionizable lipid, and optionally a neutral phospholipid. The lipid-based topical injection formulation enables enriched delivery of drugs at an injection site and efficient expression of proteins for a prolonged period of time. This disclosure also relates to a method of preparing the lipid-based topical injection formulation, and use of the lipid-based topical injection formulation in the delivery of biologically active substances such as nucleic acids (e.g., mRNA, miRNA, siRNA, saRNA, ASO, DNA, etc.).